Navigation Links
Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
Date:5/15/2012

and regulatory clearances even if successful will lead to product advancement or partnering; that that FDA or other regulatory clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that new collaborative partners will be found; that additional product opportunities will be established; or that that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®,
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Ranbaxy Laboratories ... Co., Ltd. (hereafter, Daiichi Sankyo), announced on May ... recent years to address past conduct under prior ... Daiichi Sankyo continues to support Ranbaxy ... conduct of the past which led to the ...
(Date:5/22/2013)... 22. Mai 2013  Grifols, ein globales ... Barcelona , Spanien, präsentierte die ... höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den ... (AAT) auf ein Niveau anhebt, das innerhalb ... liegt. ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, ...
(Date:5/22/2013)... and REHOVOT, Israel , May 22, ... ), a leading developer and provider of microRNA-based molecular ... , President and Chief Executive Officer of Rosetta Genomics, ... Healthcare Conference taking place from June 3-6, 2013 in ... on Tuesday, June 4 th at 2:00 p.m. ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
... N.J., Jan. 4, 2012   CANTEL MEDICAL CORP. ... CEO, will be presenting at the Needham & Company, ... scheduled for 9:20 AM ET on Wednesday, January 11, ... Q & A session immediately following the presentation. In ...
... marketers who need to calibrate multi-channel marketing and sales ... SyntheSight™ , a new proprietary pharmaceutical ... patent-pending IntelliScore™ , provides actionable insights ... answers. SyntheSight ...
Cached Medicine Technology:RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 2RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 3
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Fish oil ... 2 diabetes, new research suggests. The ... levels of a hormone called adiponectin that,s linked ... of this hormone in the bloodstream have also ... disease. "While prior animal studies found fish ...
(Date:5/22/2013)... at Massachusetts General Hospital (MGH) one of the ... half rated the training they had received in addiction ... Significant numbers felt unprepared to diagnose or treat such ... response to the findings, recently published online in the ... residents, training in addiction medicine. , "Our residents ...
(Date:5/22/2013)... effect does a father,s depression have on his young son ... intimacy in their marriage, their children benefit, said a University ... their child, they need to be able to attend to ... stage and abilities, and notice whether he is getting frustrated ... said Nancy McElwain, a U of I professor of human ...
(Date:5/22/2013)... A new study suggests that disturbed sleep in ... and greater uncertainly about future success. However, ... appears to have a protective effect. , ... with depressed mood and greater uncertainty about future ... and from teachers were associated with significantly fewer ...
(Date:5/22/2013)... "power plants" that make energy to keep cells alive ... of the drug-resistant forms of cancer source of ... conclusion of a new study published in the journal ... and colleagues explain that doxorubicin and other common forms ... nucleus of cancer cells. Cancer cells divide and multiply ...
Breaking Medicine News(10 mins):Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2Health News:Survey points out deficiencies in addictions training for medical residents 2Health News:Survey points out deficiencies in addictions training for medical residents 3Health News:Survey points out deficiencies in addictions training for medical residents 4Health News:Good marriage can buffer effects of dad's depression on young children 2Health News:Parent and teacher support protects teens from sleep problems and depression 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... present at the 12th Annual Sidoti Emerging Growth,Institutional ... p.m. (ET) at the,Grand Hyatt Hotel in New ... global healthcare supplier that develops,manufactures and distributes over-the-counter ...
... will be a covered benefit immediately upon its ... members with chronic lymphocytic leukemia, INDIANAPOLIS, March ... effective immediately upon the drug,s,availability, its affiliate health ... coverage for Treanda. Specific benefit plans,may have variable ...
... Natural,Nutrition, Inc. (OTC Bulletin Board: NTNI) ... Finance, Inc., has been,renamed i-Nutrition, Inc. As the ... lending activities of CSI Business Finance have been ... all proceeds from loan payments,received going forward will ...
... Medicine and the Fox Chase Cancer Center have announced ... to join the Temple faculty and train Temple graduate ... share strengths and resources to collaborate on a new ... to those made between other medical schools and cancer ...
... Sharps Compliance Corp.,(OTC Bulletin Board: SCOM) ("Sharps" ... for small quantity generators of,medical waste, announced today ... Senior Vice President of Operations. Mr. Aladwani joins ... developer and,manufacturer of medical devices, where he served ...
... Southwestern Medical Center Patients Will Be the First to Benefit ... ... HOFFMAN ESTATES, Ill., March 24 Siemens Healthcare, (http://www.siemens.com/healthcare ) ... technology at UT Southwestern Medical,Center in Dallas. The facility will ...
Cached Medicine News:Health News:WellPoint's Health Plans to Cover Newly Approved Cancer Treatment 2Health News:Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc. 2Health News:Temple and Fox Chase partner on research and education 2Health News:Temple and Fox Chase partner on research and education 3Health News:Temple and Fox Chase partner on research and education 4Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 2Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 3Health News:Siemens Installs First High-Definition PET-CT 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: